Palo Alto, California – April 17, 2025: RISA Labs has raised a $3.5M funding spherical to assist healthcare organizations eradicate some of the persistent boundaries to well timed most cancers care: prior authorization delays. RISA Labs has already confirmed that sooner care is feasible by dramatically decreasing handbook workflows and administrative burden.
The seed was led by Binny Bansal (Flipkart co-founder) with participation from Oncology Ventures, Basic Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The capital will speed up deployments within the subsequent 100 most cancers facilities throughout the nation inside the subsequent two years.
“Prior authorizations stay one of many least automated components of our healthcare system,” mentioned Ben Freeberg, Managing Accomplice at Oncology Ventures. “In oncology, the stakes are larger. 70% of most cancers sufferers expertise delays in care due to prior authorization necessities. In 33% of these circumstances, the delay is one month—a time window that may improve the danger of loss of life by 13 p.c in sure most cancers varieties. The present system isn’t simply inefficient – it’s harmful.”
RISA’s platform—Enterprise Working System as a Service (BOSS) – will not be one other automation bot or AI assistant. It’s a full-stack orchestration engine constructed for the vertical complexity of healthcare, As an alternative of counting on people to push paperwork or brittle bots that break when techniques change, BOSS decomposes complicated workflows into micro-tasks, then delegates them to a community of clever brokers—LLMs, digital twins, and reinforcement learners, extending throughout an establishment’s complete software program stack. This enables BOSS to create a parallel digital workforce, working on behalf of groups and alongside them. A 1,000-person establishment can perform like a 2,000-person one in a single day, with digital brokers making up half the workforce.
“We’ve had Home windows, we’ve had Linux, we’ve had Mac, every OS helped people extract extra from machines. However now, we’re drowning in software program. There’s an excessive amount of of it, and a scarcity of expert labor to function it. Software program that was presupposed to get work accomplished has change into work itself,” Kshitij Jaggi, co-founder and CEO of RISA Labs provides. “BOSS is an AI OS designed for the post-ChatGPT period : the place work is not about studying instruments, however merely expressing intent.”
At a number one US most cancers middle, BOSS lowered prior authorization instances from half-hour to underneath 5. In only a few months, it processed over $1 million in medicines, freed up 80 p.c of employees time, and reduce administrative prices by 66 p.c.
“Most cancers care is time delicate. Each delay in therapy can have an effect on outcomes. Prior authorizations proceed to sluggish us down. What RISA is constructing isn’t just good know-how. It removes boundaries so our groups can transfer sooner and keep centered on what issues most: caring for sufferers,” mentioned Dr. Jeffrey Vacirca, CEO of New York Most cancers and Blood Specialists.
Primarily based in Silicon Valley, RISA was based by IIT Kanpur alumni and serial founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO), longtime buddies for over a decade who beforehand constructed and scaled City Well being. Their frustration with fragmented, sluggish, and error-prone healthcare workflows throughout that journey impressed the duo to take a systems-first method, main them to develop a foundational AI working system that may simulate, perceive, and orchestrate complete institutional workflows from finish to finish.
“BOSS is low-entropy system design to carry circulation state in system-2 considering for LLMs; it goals to maximise AI brokers’ usefulness for crucial issues like oncology operations,” mentioned Kumar Shivang, co-founder & CTO of RISA. “Its orchestration layer then turns that intelligence into exact, real-time execution with integrations with techniques of document like Flatiron Well being’s EMR.”
RISA’s founding workforce first explored these ideas via analysis, co-authoring ‘Digital Twin Ecosystem in Oncology Scientific Operations’—an early effort to check smarter, AI-driven most cancers care workflows. This foundational work laid the conceptual groundwork that later translated into tangible enhancements in real-world oncology operations.
RISA’s platform alerts a broader shift in enterprise AI. “As AI brokers unbundle the $4.6 trillion companies trade, RISA’s BOSS leads the best way—confirmed in oncology and constructed to scale,” mentioned Binny Bansal, co-founder —of Flipkart and lead investor.
Wanting forward, RISA plans to increase throughout a number of nodes inside the oncology ecosystem, positioning itself because the AI transformation associate for each operational and medical workflows. This contains enabling coordination and intelligence throughout suppliers, life sciences organizations, and different stakeholders all through the journey of a drug – extending the corporate’s long run imaginative and prescient to constructing a unified layer for AI-driven orchestration in oncology.
